Kornimate/medical-research-clean huggingface dataset:
a diagnostic sij injection following a composite of 3 diagnostic tests and a pain referral diagram

Conditions: Sacroiliac Injection

Summary: the purpose of this study is to determine the predictive value of a composite of 3 simple clinically practical diagnostic tests (mekhail's test, patrick's and thigh thrust) combined with a pain referral diagram in predicting response to a single diagnostic sij injection.

the purpose of this study is to determine the predictive value of a composite of 3 simple, clinically practical, diagnostic tests (mekhail, patrick's and thigh thrust) combined with a pain referral diagram in predicting response to a single diagnostic sij injection. the goal is to test these 3 tests and compare their predictive value to the 6 tests commonly reported in the literature in order to provide a clinician with clinically practical special tests to aide in the diagnosis and treatment of sij mediated pain. . specifically, we seek to evaluate the prognostic capacity for a series of three clinical tests (mekhail's test, thigh thrust and patrick's test) combined with a pain referral diagram to accurately predict the response (change in vas) of a single diagnostic sacroiliac joint and extra-capsular joint injection.

Eligibility criteria:
inclusion criteria: * any patient presenting with low back pain with or without radicular symptoms, regardless of prior history of back surgery from 18-90 years old whom after being evaluated by an independent clinician in the cleveland clinic pain clinic has been scheduled for a diagnostic sij injection. exclusion criteria: * any patient less than 18 or greater than 90 years old, has any medical condition that would not allow them to complete the study, diagnosis of any recent fractures in the lumbar spine, recent infection, pregnancy, taking anticoagulants.
a new minimal-invasive brain tissue probe applying near infrared spectroscopy

Conditions: Spontaneous Subarachnoid Hemorrhage

Summary: to assess the feasibility of a new brain tissue probe for multi-parameter neuromonitoring (nemo probe) and the accuracy of measurement values. to demonstrate the ability of the nemo probe to detect changes in cerebral hemodynamics and oxygenation during cerebrovascular events monitored with established methods including brain tissue oxygenation tension and microdialysis


Eligibility criteria:
inclusion criteria: * males and females aged 18-75 years (inclusive) * patients with high-grade subarachnoid hemorrhage (wfns 4-5) * decreased level of consciousness with the need for intracranial pressure monitoring * successful exclusion of the ruptured aneurysm with clipping or coiling * women of childbearing potential must have a negative serum pregnancy test * written informed consent obtained by a legal representative exclusion criteria: * significant kidney and/or liver disease * any severe unstable concomitant condition or disease (e.g. cancer, coronary disease) or chronic condition (e.g. psychiatric disorder, chronic obstructive pulmonary disease grade ii, chronic heart failure \> nyha ii) * cerebrospinal fluid infection or signs of meningoencephalitis * acute respiratory distress syndrome (ards), pulmonary edema * preexisting coagulation disorder * patients with current alcohol or drug abusus or dependence * patients with a history of hypersensitivity against indocyanine green or sodium iodine * patients with thyroid disease causing hyperthyroidism * breast-feeding women * patients committed to an institution based on official directive or court order
efficacy and tolerability of hirudoid cream in prophylaxis and treatment infusion phlebitis

Conditions: Thrombophlebitis; Phlebitis

Summary: patients receiving nutritional emulsion for at least 3 days will be treated with hirudoid cream or placebo cream to prevent and treat phlebitis caused by the infusion. the treatment is continued after the end of infusion for at least 7 days. number of patients developing superficial phlebitis and duration of phlebitis will be recorded.


Eligibility criteria:
inclusion criteria: * patients who are admitted to the hospital requiring to receive infusion of a complete nutritional emulsion for 3 days (kabiven® peripheral, 1400 kcal, 1920 ml, 750 mosmol/l, ph 5.6), * aged 18-65 years. * patients who are able to understand the requirements of the study and agree to sign an informed consent, approved by an independent ethic committee (iec)/institutional review board (irb), prior to the study. exclusion criteria: * patients known to be allergic to hirudoid or any ingredients of hirudoid * patients with impaired skin integrity caused by lesion or soft tissue trauma * patients having skin lesions with ulcerations or any other severe dermatologic disease * patients has been received a complete nutritional emulsion infusion within 7 days of inclusion * patients with severe uncontrolled medical conditions, which makes it undesirable or unsafe for the patients to participate in the study, such as: acute or chronic uncontrolled severe infections,unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction, serious uncontrolled cardiac arrhythmia or any other clinically serious cardiac disease, uncontrolled diabetes as defined by fasting serum glucose \> 1.5 x uln; optimal glycaemic control should be achieved before starting trial therapy, uncontrolled bleeding * patients known to have coagulation disorders such as haemophilia, thrombocytopenia, thrombosis, other severe hematologic conditions like leukaemia, especially with abnormal coagulation * patients who have symptoms of microangiopathy (small vessel disease) or neuropathy related to diabetes and other diseases * patients with hyperthyroidism and hypothyroidism * patients who are pregnant or breast feeding * patients who are on anticoagulant therapy (last 2 weeks) * patients with severe psychiatric conditions * patients who are unable to bear legal responsibility or unable to understand the study * patients who are unreliable or unable to comply with the protocol, like alcohol or drug abusers * patients who had been participated in another clinical trial in the past 12 weeks * patient is relatives of, or staff directly reporting to, the investigator * patient is employee of the sponsor

Keywords: mucopolysaccaride polysulfate (mps) mps heparinoide infusionphlebitis prevention superficial thrombophlebitis treatment
a prospective birth cohort of infants with allergy and neurodevelopmental disorders in china

Conditions: Child Allergy; Neurodevelopmental Disorders

Summary: in this study, a birth cohort was established to demonstrate the causal relationship between allergies and neurodevelopment disorders in infants and young children, and to find out the influencing factors of neurodevelopment disorders in early life.

in this study, a birth cohort was established, and infants were divided into two groups according to inclusion and exclusion criteria ( see study design ). one group was allergic group, and the other group was control group. the two groups will be followed up for up to 6 years, and specimens ( blood, urine, feces ) and test data ( height, weight, gesell, etc. ) will be retained during the follow-up period. the outcome indicators were asd, adhd or ld, and dsm-5 was used as the diagnostic criteria.

Eligibility criteria:
inclusion criteria: * ①allergic questionnaire results were positive. * the living area is jinan city and its surrounding areas in shandong province, which is convenient for follow-up. exclusion criteria: * there is a clear diagnosis of brain developmental disorders * psychological diseases * history of craniocerebral trauma or brain organic disease ④major physical diseases ⑤visual and auditory disorders ⑥ epilepsy ⑦intellectual disabilities
management of drooling in children with cerebral palsy in france

Conditions: Cerebral Palsy; Pathological Drooling

Summary: the study is a transversal, observational, descriptive survey of the practices and opinions of health professionals carried out nationally across france that aims to characterize children with cerebral palsy and pathological drooling and to describe care pathways, assessment and treatment of drooling.


Eligibility criteria:
inclusion criteria: * health professional known to assess and/or treat drooling * health professional known to assess and/or treat children with cerebral palsy * health professional exercising in france exclusion criteria: * health professional with an inactive e-mail address

Keywords: drooling cerebral palsy botulinium toxin practice survey of health professionals children
a prospective cohort of children with hiv infection

Conditions: HIV Infections

Summary: to evaluate clinical and immunological outcome of children treated with haart.

this is a long term cohort study that was started in 2002. currently, there are 120 children enrolled in the study and are receiving hiv care according to standard practice set by the thai ministry of public health. hiv-infected parents also receive care at the same clinic.

Eligibility criteria:
inclusion criteria: * children who are part of the atc program at chulalongkorn hospital and at hiv-nat, the thai red cross aids research center * children who fulfil criteria to start haart according to the atc program * children who are switched to second regimen or salvage therapy * children who are on any antiretroviral regimens, including post trial children from other hiv-nat study (both at hiv-nat and khon kaen university sites) * children with hiv infection who are not on antiretroviral therapy * caretakers understand the purpose of data and plasma samples collection, and have signed the consent form exclusion criteria: * patients and caretakers may choose to stop haart at anytime during the study. if they agree, we would continue to follow them in this study.

Keywords: hiv children haart arv second line haart viral load combination drug treatment experienced treatment naive
penile lengthening pre-penile prosthesis implantation

Conditions: Erectile Dysfunction

Summary: this study is intended to utilize a novel, class i (ie. lowest risk, clinical studies not required) medical device to determine whether penile length can be increased in men prior to undergoing a penile prosthesis implantation procedure.

men with erectile dysfunction, unresponsive to conservative therapies, are recommended to undergo placement of an inflatable penile prosthesis (ipp); however, it is a common complaint post-operatively that their penis length is shorter than what it was previously. several attempts have been made by investigators to optimize penile length prior to placement of the penile prosthesis. compared to other options, penile traction therapy (ptt) offers several potential advantages in that it is minimally-invasive, does not increase the morbidity of surgery, and has not been shown to result in any long-term side effects. a new penile traction device (restorex® ) was created and funded through mayo ventures. given the clinical issue of dissatisfaction with penile length post ipp, the potential role for ptt, and limited amount of data available, we sought to perform a clinical trial evaluating the effect of ptt on increasing the total length of prosthesis which can be inserted. we additionally sought to determine if ptt resulted in improved post-operative satisfaction on total penile length achieved. to accomplish the study, a population of men from mayo clinic planning to undergo placement of an ipp will be enrolled and given the option to either join the control (no treatment) group or ptt group for 3 months prior to their procedure. outcomes will be assessed prior to surgery and 3, 6, and 12 months post-procedure. results are to be used with the intent to publish in a scientific journal.

Eligibility criteria:
inclusion criteria * men undergoing placement of a penile prosthesis * must be the first time a penile prosthesis is implanted * undergoing implantation of a 3-piece inflatable penile prosthesis exclusion criteria * prior ischemic priapism * any prior penile prosthesis surgeries * any prior penile surgeries other than circumcision * undergoing malleable penile prosthesis or ambicor device
study to assess change in disease activity of risankizumab treatment in adult participants with moderate to severe ulcerative colitis

Conditions: Ulcerative Colitis

Summary: ulcerative colitis (uc) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large intestine). this study will assess the change in disease activity of risankizumab treatment in adult participants with moderate to severe uc in real-world clinical practice. risankizumab is an approved drug for treating participants with ulcerative colitis. approximately 200 participants who are prescribed risankizumab by their physician in accordance with local label will be enrolled in approximately multiple sites across germany and austria. participants will receive risankizumab as prescribed by their physician according to their routine clinical practice and local label. participants will be followed for up to 52 weeks. there is expected to be no additional burden for participants in this trial. participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.


Eligibility criteria:
inclusion criteria: * participants with an endoscopically confirmed diagnosis of moderate to severe ulcerative colitis. * participants initiating risankizumab at the investigator's discretion as part of their routine clinical care; the decision to administer risankizumab must be made prior to and independent of documentation for the study and according to the approved local label. exclusion criteria: * participants previously exposed risankizumab * participants who are currently participating in interventional research (not including noninterventional studies, post-marketing observational study (pmos), or registry participation).

Keywords: ulcerative colitis risankizumab skyrizi
a pilot study to explore the role of gut flora in myasthenia gravis

Conditions: Myasthenia Gravis; Myasthenia Gravis, Generalized

Summary: this study seeks to correlate microbiome sequencing data with information provided by patients and their medical records.

the goal of this research study is to better understand how the genetic information in subject's microbiome correlates to myasthenia gravis.

Eligibility criteria:
inclusion criteria: 1. signed informed consent, demonstrating that the patient understands the procedures required for the study and the purpose of the study a. may be signed by parent or legal guardian in the case of minor or adult unable to provide consent 2. male or female of all ages. 3. diagnosis of myasthenia gravis by a physician exclusion criteria: 1. refusal to sign informed consent form 2. history of bariatric surgery, total colectomy with ileorectal anastomosis or proctocolectomy. 3. postoperative stoma, ostomy, or ileoanal pouch 4. participation in any experimental drug protocol within the past 12 weeks 5. treatment with total parenteral nutrition
volatility and heterogeneity of vaccine sentiments means continuous monitoring is needed when measuring message effectiveness

Conditions: Vaccine-Preventable Diseases; Vaccine Refusal

Summary: the success of vaccination programs often depends on the effectiveness of the vaccine messages, particularly during emergencies such as the covid-19 pandemic. the current suboptimal uptake of covid-19 vaccines across many parts of the world highlights the tremendous challenges in overcoming vaccine hesitancy and refusal even in the context of a world-devastating pandemic. the investigators conducted a randomized controlled trial in hong kong to evaluate the impact of seven vaccine messages on covid-19 vaccine uptake (with the government slogan as the control). the participants included 127,000 individuals who googled covid-19-related information during july-october 2021.

this study aims to evaluate the effectiveness of using the google advertising platforms on influencing the uptake of covid-19 vaccines in hong kong. when completed, the rich database compiled through this proposed study will provide increased insight into vaccine hesitancy in hong kong. insights from the optimised online advertising trial can aid in providing crucial technical and theoretical support to the relevant health authorities for any potential evidence-based policy intervention in addressing vaccine hesitancy issues or the public's concerns towards vaccines in hong kong.

Eligibility criteria:
inclusion criteria: * general users of google search in hong kong exclusion criteria: * none

Keywords: vaccine hesitancy google ads vaccine messages vaccine confidence
laser therapy treatment of peri-implantitis.

Conditions: Peri-implantitis

Summary: the primary objective of this study is to compare the clinical outcomes of using er: yag laser along with bone graft and barrier membrane to conventional mechanical debridement also with bone graft and barrier membrane in the treatment of peri-implantitis infections.


Eligibility criteria:
inclusion criteria: * patients, aged 18 - 85 years * physical status according to the american society of anesthesiologists (asa) i or ii, which includes patients who are systemically healthy or suffer under mild to moderate, but well controlled systemic diseases. * patients having a minimum of 1 dental implant with peri-implantitis. * the dental implant with peri-implantitis has ≥ 3 threads exposed or pocket probing depth (ppd) ≥ 5mm, with bleeding on probing (bop) and/or suppuration (pus). * the implants are in function for at least 6 months * no uncontrolled systemic disease or condition known to alter bone metabolism, like osteoporosis, osteopenia, hyperparathyroidism, paget's disease. * only rough surface implant will be included in this study exclusion criteria: * long-term use of antibiotics \> 2 weeks in the past two months * no peri-implantitis treatment in the last 2 months * patients taking medications known to modify bone metabolism (such as bisphosphonates, corticosteroids, hormone replacement therapy for menopausal women, parathyroid hormone, denosumab, strontium ranelate). * pregnant females or those planning to become pregnant. * patients with a history of medically diagnosed oral cancer, bisphosphonate usage, sepsis or those having adverse outcomes to oral procedures in the past, will be excluded * mobility of dental implants * history of alcoholism or drug abuse * current smokers or quit smoking less than 6 months * diseases of the immune system or any medical condition that may influence the outcome (uncontrolled diabetes (hba1c \>7) * patients with allergies known to affect one or more of the treatment provided in this study * polish surface implants * implants with trabecular surface
from fear to purpose act protocol. implications of death anxiety in depression and anxiety symptoms.

Conditions: Death Anxiety; Depression; Anxiety

Summary: the main purpose of this placebo controlled trial is to test the efficacy of a one-session from fear to purpose act intervention in reducing self-reported death anxiety levels. another objective of this study is to investigate whether reductions in death anxiety levels are associated with reductions in depression and anxiety levels, thus testing if death anxiety is a transdiagnostic factor involved in psychopathology.

this is a placebo controlled trial where the main objective is to test if the one-session from fear to purpose act intervention is effective in reducing self-reported death anxiety levels. a secondary objective is to investigate whether reductions in death anxiety levels are associated with reductions in depression and anxiety levels, thus testing if death anxiety is a transdiagnostic factor involved in psychopathology. participants will be selected based on death anxiety levels (moderate-high scores) and depression and anxiety symptoms (subclinical levels). minors, people with suicidal ideation, people with current psychological/psychiatric diagnosis (excepting depression or anxiety diagnosis), people in active psychological/psychiatric treatment will be excluded. recruited participants will be randomized into two groups: the experimental group (will receive the from fear to purpose act intervention) and the placebo group. the placebo condition will be undergoing a group-based attentional control activity. participants will be blinded to the study condition. the from fear to purpose intervention protocol is based on acceptance and commitment therapy (act) strategies, build around identifying and committing to personal values. the intervention will be group-based (90 minutes session). the intervention will be administered by experienced psychotherapists. the primary outcome is death anxiety, while secondary outcomes are depression and anxiety symptoms, well-being, psychological flexibility, experiential avoidance and valued living.

Eligibility criteria:
inclusion criteria: * moderate-high levels of death anxiety (score \> or = 55) and * subclinical levels of depression (score \> or = 9) and/or * subclinical levels of anxiety (score \> or = 9) exclusion criteria: * minors * suicidal ideation * current psychological/psychiatric diagnosis (except depression or anxiety diagnosis) * active psychological/psychiatric treatment

Keywords: death anxiety depression anxiety transdiagnostic indirect intervention rct
sensors for communication for persons who cannot communicate unequivocally

Conditions: Intellectual Disability; Autism; Cerebral Palsy

Summary: some persons with intellectual disability or comprehensive cerebral palsy cannot communicate unequivocally how they are, how they react to situations and people, whether they are in pain or experience discomfort, anger or fear. their modes of communication (sounds, grimacing etc) may be unintelligible or ambiguous to their caregivers. with the use of heart and/or respiration monitors the investigators aim to give these persons a means to communicate their immediate reactions or responses. the respiration monitor is meant to register sleep at night, so that the participants can communicate whether they have slept well or not the previous night.

heart rate (hr) is considered to reflect a persons autonomic response to situations, whether external (what happens around us) or internal (pain or pleasure, joy or fear). some persons with severe intellectual disability or comprehensive cerebral palsy or childhood autism cannot communicate unequivocally, either because they lack the cognitive prerequisites and language or because they lack control over their muscles used for speech. the investigators believe that these persons, through their heart rate, as registered with a commercially available chest belt or wrist watch, may communicate something about their well being and their reactions, preferences, aversions and fears. many persons with intellectual disability, comprehensive cerebral palsy or childhood autism (the participants in this study) have sleep problems, but these may go unnoticed. participants often have a fixed schedule for the day, and this is carried out irrespective of the shape they are in, e.g. irrespective of how well they have slept the night before. the challenges may then be too much for a sleep-deprived person, and frustration and even self harm and aggressive behavior may be the result. with the use of a respiration monitor that assesses sleep from the person's breathing pattern, the person in question may be able to communicate to her/his caregivers how the previous night's sleep was. information about heart rate and sleep may contribute to better care and health services for persons who are unable to communicate unequivocally because of intellectual disability, autism and/or cerebral palsy.

Eligibility criteria:
inclusion criteria: * intellectual disability with or without autism and/or cerebral palsy that render the participant unable to communicate his/her needs and reactions unequivocally. exclusion criteria: * allergic skin reaction to chest strap